Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Edwards Lifesciences
The ACTIVE Trial is a prospective, randomized, multicenter trial. Patients with clinically significant functional mitral regurgitation will be randomized 2:1 to receive either transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT) or GDMT alone. Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 5 years.
Patient hospitalized due to heart failure during 12 months prior to submission to Central Screening Committee OR elevated Brain Natriuretic Peptid (BNP);
Patient is able and willing to give informed consent and follow protocol procedures, and comply with follow-up visit compliance.
You may not be if
Primarily degenerative MR;
Mitral annular calcification that would impede implantation of device;
Other severe valve disorders requiring intervention;
Mitral valve anatomy which may preclude proper Edwards Cardioband deployment;
Life expectancy of less than twelve months;
Patient is participating in concomitant research studies of investigational products which have not reached their primary endpoint;
Unwillingness or inability to undergo follow-up investigations/visits;
Other medical, social, or psychological conditions that precludes appropriate consent and follow-up